CLINICAL TRIAL: CANDIDIASIS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 新生儿念珠菌病是一种致死性疾病，人们对此知之甚少。尽管可归因死亡率为30%，但目前诊断新生儿念珠菌病的金标准（正常无菌体液的重复培养）的敏感性为50%;目前还没有前瞻性研究来建立经验性治疗的指南。 该方案将建立一个由1,750名出生体重< 1000克的婴儿组成的前瞻性队列，以评估三种新的诊断测试并开发侵袭性念珠菌病的风险分层模型。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Neonatal candidiasis is a lethal disease that is poorly understood. Despite an attributable mortality of 30%, the current gold standard for the diagnosis of neonatal candidiasis (repeated culture of normally sterile body fluid) has a sensitivity of 50%; and there have been no prospective studies to establish guidelines for the initiation of empirical treatment. This protocol will establish a prospective cohort of 1,750 infants born < 1000 grams birthweight in order to evaluate three new diagnostic tests and develop a risk stratification model for invasive candidiasis.